Li H, Duan Z, Zhao C, et al. - For synchronous extracranial oligometastatic non-small cell lung cancer (NSCLC), researchers compared the combination of brachytherapy with iodine-125 seeds and systemic chemotherapy vs systemic chemotherapy alone in terms of effectiveness and safety. They analyzed data from 69 NSCLC patients with extracranial oligometastatic NSCLC split into two therapy groups. Group A included 32 patients who were treated with brachytherapy with iodine-125 seeds combined with systemic chemotherapy, and group B with the remaining 37 patients who received chemotherapy alone. Group A vs group B had a significantly higher overall 3-month objective response rate. The progression-free survival was estimated to be 11.6 months vs 6.3 months and overall survival was estimated to be 17.6 months vs 11.2 months in groups A and B, respectively, when patients were observed for a median span of 23 months. Overall, findings demonstrated the superiority of the combination of brachytherapy with iodine-125 seeds and systemic chemotherapy vs chemotherapy alone for the treatment of synchronous extracranial oligometastatic NSCLC.